Real-world experience with subcutaneous infliximab: broadening treatment strategies for inflammatory bowel disease
Introduction The first subcutaneous (SC) formulation of infliximab (IFX), CT‑P13 SC, has
been approved in Europe and Australia, including for the treatment of inflammatory bowel …
been approved in Europe and Australia, including for the treatment of inflammatory bowel …
Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and …
J Harno-Tasihin, L Siregar, M Paajanen… - Scandinavian Journal …, 2024 - Taylor & Francis
Abstract Objective Subcutaneous (SC) infliximab (IFX) and vedolizumab (VDZ) have recently
become available. We aimed to examine the impact of switching from intravenous (IV) to SC …
become available. We aimed to examine the impact of switching from intravenous (IV) to SC …
Inflammatory bowel disease patients' acceptance for switching from intravenous infliximab or vedolizumab to subcutaneous formulation: The Nancy Experience
C Remy, B Caron, C Gouynou, V Haghnejad… - Journal of Clinical …, 2022 - mdpi.com
Background: Subcutaneous infliximab and vedolizumab formulations have been developed
for maintenance therapy in inflammatory bowel disease. The objective of this study was to …
for maintenance therapy in inflammatory bowel disease. The objective of this study was to …
Benefits of Biosimilars in the Management of Patients with Inflammatory Bowel Disease: An International Survey
F D'Amico, L Peyrin-Biroulet, S Danese - Journal of Clinical Medicine, 2024 - mdpi.com
Background/Objectives: The development of biosimilar drugs has revolutionized the
management of patients with inflammatory bowel diseases (IBD), significantly reducing …
management of patients with inflammatory bowel diseases (IBD), significantly reducing …
Long‐term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified …
A Buisson, M Nachury, M Bazoge… - Alimentary …, 2024 - Wiley Online Library
Background The long‐term risk of relapse after switching from intravenous (IV) to
subcutaneous (SC) infliximab remains unknown in inflammatory bowel disease (IBD). Aims …
subcutaneous (SC) infliximab remains unknown in inflammatory bowel disease (IBD). Aims …
[HTML][HTML] Switching from intravenous to subcutaneous infliximab maintenance therapy in inflammatory bowel disease: Post hoc longitudinal analysis of a randomized …
S Schreiber, G D'Haens, F Cummings, PM Irving… - Digestive and Liver …, 2024 - Elsevier
Background Pharmacokinetic non-inferiority of subcutaneous (SC) to intravenous (IV) CT-
P13 maintenance therapy was demonstrated in a randomized trial (NCT02883452). This …
P13 maintenance therapy was demonstrated in a randomized trial (NCT02883452). This …
Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials
Abstract Background and Aims CT-P13 subcutaneous (SC), an SC formulation of the
intravenous (IV) infliximab biosimilar CT-P13 IV, creates a unique exposure profile. We …
intravenous (IV) infliximab biosimilar CT-P13 IV, creates a unique exposure profile. We …